Trefoil Therapeutics key facts
as of Oct 2026- Developer of corneal therapeutics designed to facilitate the treatment of ophthalmic diseases.
- Trefoil Therapeutics is valued at approximately $59.5M as of Oct 2026, set at its later-stage round, May 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $49.7M across 4 recorded rounds; the latest was Seed Round ($4.6M) in Apr 2025.
- Notable investors include National Institutes of Health, CONNECT(San Diego), Correlation Ventures, Hatteras Venture Partners, FemHealth Ventures — 12 tracked in total.
- Trefoil Therapeutics has filed 5 Form Ds with the SEC since 2016, most recently May 2025 ($4.6M sold to 16 investors).
- Status: Privately Held (backing).
Valued at $59.5M at its later-stage round, May 2025. Nothing has traded since.
- ·The complete investor list: 12 names
- ·Watch Trefoil Therapeutics: the Monday email on marks, rounds and moves
Trefoil Therapeutics funding rounds
4 roundsWho backs Trefoil Therapeutics
12+Trefoil Therapeutics valuation
Trefoil Therapeutics was valued at $59.5 million at its later-stage round in May 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Trefoil Therapeutics raised?
Trefoil Therapeutics has raised $49.7 million across 4 recorded rounds since 2016. The largest was a $4.6 million seed round in Apr 2025.
Trefoil Therapeutics has filed 5 Form Ds with the SEC since 2016, most recently in May 2025 ($4.6 million sold to 16 investors).
Trefoil Therapeutics investors
12 investors are on record for Trefoil Therapeutics, including National Institutes of Health, CONNECT(San Diego), Correlation Ventures and Hatteras Venture Partners. The seed round in Apr 2025 drew 16 investors.
About Trefoil Therapeutics
Developer of corneal therapeutics designed to facilitate the treatment of ophthalmic diseases. The company's therapy is focused on leveraging its engineered fibroblast growth factor-one protein technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases and help regenerate the endothelial cell layer and eliminate the symptoms associated with this condition that leads to the loss of vision, enabling ophthalmologists to treat patients with severe corneal endothelial diseases and epithelial disorders.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2013
- Employees
- 10
- Website
- trefoiltherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.